Shares of Tourmaline Oil Corp. TOU slipped 3.33% to C$68.30 Thursday, in what proved to be an all-around poor trading session ...

Tourmaline Oil Corp. closed 0.3% short of its 52-week high of C$70.83, which the company achieved on February 21st.

Tourmaline welcomes back Jeff Zuckerman as Managing Director, who rejoins the firm after four years bringing his expertise ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.

Behavior indicators including the rising 40wMA confirm the bullish potential. There is good support near $64-65; only a ...

– Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in ...

Ridker, and Tabassome Simon – – Cash, cash equivalents, and investments of $294.9 million as of December 31, 2024, providing expected cash runway into the second half of 2027 – NEW YORK, March 13, ...

Tourmaline Capital Partners bought the 12-story building for $15 million less than its previous owners acquired it for in ...

The office market in Coral Gables has attracted major tenants such as Apple, FIFA and Bank of America, and with a direct vacancy rate of 8.2%, the submarket has become one of the most sought-after in ...

My last article some years back noted that Charlie Lake had a lot of profit potential, and Tourmaline was there first. As the slide above shows, Charlie Lake has one of the best profit potentials ...

Biotech Analyst Devarakonda discusses cardiovascular disease with CV expert and Tourmaline Bio management (TRML) on an Analyst/Industry ...